



April 5, 2022

✓ **BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

**Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations  
and Disclosure Requirements) Regulations, 2015.**

**Sub: U.S. FDA inspection at the Company's Tarapur manufacturing facility**

***Dear Sir/Madam,***

The U.S. FDA has concluded an inspection at the Company's Tarapur manufacturing facility. The inspection was carried out between March 22, 2022 and April 4, 2022.

The inspection closed with four observations. We are confident of addressing the observations to the U.S. FDA's satisfaction. We are committed to adherence and full compliance with CGMP regulations and uphold the highest quality standards across our manufacturing sites.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

Thanking you,

**FOR LUPIN LIMITED**



**R. V. SATAM  
COMPANY SECRETARY  
(ACS -1 1973)**

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)